You searched for "Cancer"

802 results found

The role of specialist therapeutic radiographers in the treatment and care of men with prostate cancer

The Statement of Intent: Cancer Strategy for England: 2015-2020 indicates that the number of people diagnosed with cancer each year will continue to grow rapidly due to the ageing population. There is also a requirement to diagnose and offer patients...

Action Bladder Cancer UK launches learning module for primary care

Action Bladder Cancer UK has launched a new online learning module for primary care, to help healthcare professionals improve their knowledge of bladder cancer. Bladder cancer is not a rare cancer. In the UK alone, over 23,000 people are diagnosed...

Urinary biomarkers for surveillance of non-muscle invasive bladder cancer

Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...

Factors and time to conversion from prostate cancer active surveillance to treatment

Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...

An Insider’s Perspective of Prostate Cancer – Understanding Effects, Management Options and Consequences

This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....

Incidence and risk factors of suicide after a prostate cancer diagnosis

This is an observational study looking at 1,281,393 men diagnosed with prostate cancer and 842,294 matched prostate cancer-free men. There was an overall increased relative risk of suicide of 2.01 in men diagnosed with prostate cancer compared to those without,...

Prostate cancer detection rate of MRI-TRUS fusion vs. systematic biopsy

With the advent of one-stop prostate cancer diagnostic clinics, the findings of this study are of interest to readers who may be considering introducing the technique of magnetic resonance imaging transrectal ultrasound (MRI-TRUS) fusion biopsies to their practice. A retrospective...

PET imaging of prostate-specific membrane antigen in prostate cancer

Molecular imaging utilising prostate-specific membrane antigen (PSMA) as a target has increasingly been mentioned at key conferences and meetings. PSMA is a membrane metalloenzyme that is overexpressed in prostate cancer, with the degree of expression appears to correlate with tumour...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...

The potential of statin use in castrate resistant prostate cancer treatment

One of the mechanisms by which prostate cancer achieves castrate resistance is through de novo intratumoral production of androgens. Reactivation of androgen receptors results in promotion of cell survival and proliferation pathways despite castrate serum testosterone levels. As androgen synthesis...

The importance of second-look transurethral resection for superficial bladder cancer

This was a prospective study of 100 consecutive patients with a newly diagnosed superficial bladder tumour who underwent a second look transurethral resection of bladder tumour (TURBT) two to six weeks post initial resection. This essentially included pTa multiple and...